Human CYP2C8: Structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms

Current Drug Metabolism

Volumn 10, Issue 9, 2009, Pages 1009-1047

  Lai, Xin Sheng ^a   Yang, Li Ping ^b   Li, Xiao Tian ^c   Liu, Jun Ping ^d   Zhou, Zhi Wei ^e   Zhou, Shu Feng ^e  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b BEIJING HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

^d MONASH UNIVERSITY   (Australia)

^e RMIT UNIVERSITY   (Australia)

Author keywords

Active site; CYP2C8; Inhibitor; Regulation; Structure; Substrate

Indexed keywords

ALITRETINOIN; AMIODARONE; AMITRIPTYLINE; AMODIAQUINE; ARACHIDONIC ACID; ARTELINIC ACID; AZELASTINE; CERIVASTATIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2C8; DICLOFENAC; FELODIPINE; FLUINDOSTATIN; GENISTEIN; GLUCOCORTICOID RECEPTOR; IBUPROFEN; LOPERAMIDE; METHADONE; MONTELUKAST; MORPHINE; PACLITAXEL; PHENAZONE; PIOGLITAZONE; REPAGLINIDE; RETINOID; ROSIGLITAZONE; TORASEMIDE; TROGLITAZONE; UNINDEXED DRUG; VERAPAMIL;

BIOTRANSFORMATION; CATALYST; CLINICAL PRACTICE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DNA POLYMORPHISM; DRUG BINDING; DRUG METABOLISM; DRUG STRUCTURE; ENZYME REGULATION; ENZYME SPECIFICITY; GENE MUTATION; HUMAN; IN VITRO STUDY; OXIDATION; PROTEIN STRUCTURE; REVIEW; SITE DIRECTED MUTAGENESIS; X RAY;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; GENOTYPE; HUMANS; KINETICS; MODELS, MOLECULAR; MUTATION; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 76749094018     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790711832     Document Type: Review

References (303)

1. Nebert, D. W.; Russell, D. W. Clinical importance of the cytochromes P450. Lancet, 2002, 360(9340), 1155-1162.
2. Guengerich, F. P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. Aaps J., 2006, 8(1), E101-111.
3. Totah, R. A.; Rettie, A. E. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther., 2005, 77(5), 341-352.
4. Gray, I. C.; Nobile, C.; Muresu, R.; Ford, S.; Spurr, N. K. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics, 1995, 28(2), 328-332.
5. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J. Pharmacol. Exp. Ther., 1994, 270(1), 414-423.
6. Klose, T. S.; Blaisdell, J. A.; Goldstein, J. A. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol., 1999, 13(6), 289-295.
7. Inoue, K.; Inazawa, J.; Suzuki, Y.; Shimada, T.; Yamazaki, H.; Guengerich, F. P.; Abe, T. Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1. Jpn. J. Hum. Genet., 1994, 39(3), 337-343.
8. Melet, A.; Marques-Soares, C.; Schoch, G. A.; Macherey, A. C.; Jaouen, M.; Dansette, P. M.; Sari, M. A.; Johnson, E. F.; Mansuy, D. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry, 2004, 43(49), 15379-15392.
9. Li, X. Q.; Bjorkman, A.; Andersson, T. B.; Ridderstrom, M.; Masimirembwa, C. M. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther., 2002, 300(2), 399-407.
10. Ridderstrom, M.; Zamora, I.; Fjellstrom, O.; Andersson, T. B. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J. Med. Chem., 2001, 44(24), 4072-4081.
11. Lewis, D. F. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica, 2002, 32(4), 305-323.
12. Haining, R. L.; Jones, J. P.; Henne, K. R.; Fisher, M. B.; Koop, D. R.; Trager, W. F.; Rettie, A. E. Enzymatic determinants of the substrate specificity of CYP2C9: role of B′-C loop residues in providing the π-stacking anchor site for warfarin binding. Biochemistry, 1999, 38(11), 3285-3292.
13. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424(6947), 464-468.
14. Kerdpin, O.; Elliot, D. J.; Boye, S. L.; Birkett, D. J.; Yoovathaworn, K.; Miners, J. O. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry, 2004, 43(24), 7834-7842.
15. Sullivan-Klose, T. H.; Ghanayem, B. I.; Bell, D. A.; Zhang, Z. Y.; Kaminsky, L. S.; Shenfield, G. M.; Miners, J. O.; Birkett, D. J.; Goldstein, J. A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996, 6(4), 341-349.
16. Xie, H. G.; Prasad, H. C.; Kim, R. B.; Stein, C. M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev., 2002, 54(10), 1257-1270.
17. Melet, A.; Assrir, N.; Jean, P.; Pilar Lopez-Garcia, M.; Marques-Soares, C.; Jaouen, M.; Dansette, P. M.; Sari, M. A.; Mansuy, D. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch. Biochem. Biophys., 2003, 409(1), 80-91.
18. Dai, D.; Zeldin, D. C.; Blaisdell, J. A.; Chanas, B.; Coulter, S. J.; Ghanayem, B. I.; Goldstein, J. A. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 2001, 11(7), 597-607.
19. Bahadur, N.; Leathart, J. B.; Mutch, E.; Steimel-Crespi, D.; Dunn, S. A.; Gilissen, R.; Houdt, J. V.; Hendrickx, J.; Mannens, G.; Bohets, H.; Williams, F. M.; Armstrong, M.; Crespi, C. L.; Daly, A. K. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem. Pharmacol., 2002, 64(11), 1579-1589.
20. Soyama, A.; Saito, Y.; Hanioka, N.; Murayama, N.; Nakajima, O.; Katori, N.; Ishida, S.; Sai, K.; Ozawa, S.; Sawada, J. I. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull., 2001, 24(12), 1427-1430.
21. Hichiya, H.; Tanaka-Kagawa, T.; Soyama, A.; Jinno, H.; Koyano, S.; Katori, N.; Matsushima, E.; Uchiyama, S.; Tokunaga, H.; Kimura, H.; Minami, N.; Katoh, M.; Sugai, K.; Goto, Y.; Tamura, T.; Yamamoto, N.; Ohe, Y.; Kunitoh, H.; Nokihara, H.; Yoshida, T.; Minami, H.; Saijo, N.; Ando, M.; Ozawa, S.; Saito, Y.; Sawada, J. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab. Dispos., 2005, 33(5), 630-636.
22. Schoch, G. A.; Yano, J. K.; Wester, M. R.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J. Biol. Chem., 2004, 279(10), 9497-9503.
23. Sansen, S.; Yano, J. K.; Reynald, R. L.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem., 2007, 282(19), 14348-14355.
24. Yano, J. K.; Hsu, M. H.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol., 2005, 12(9), 822-823.
25. Porubsky, P. R.; Meneely, K. M.; Scott, E. E. Structures of human cytochrome P450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J. Biol. Chem., 2008, 283(48), 33698-33707.
26. Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston, D. S.; Chenery, R. J.; Bridges, A. M. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem., 2006, 281(11), 7614-7622.
27. 3. J. Mol. Biol., 2008, 380(1), 95-106.
28. Yano, J. K.; Wester, M. R.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J. Biol. Chem., 2004, 279(37), 38091-38094.
29. Williams, P. A.; Cosme, J.; Sridhar, V.; Johnson, E. F.; McRee, D. E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell., 2000, 5(1), 121-131.
30. Schoch, G. A.; Yano, J. K.; Sansen, S.; Dansette, P. M.; Stout, C. D.; Johnson, E. F. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J. Biol. Chem., 2008, 283(25), 17227-17237.
31. Walsky, R. L.; Gaman, E. A.; Obach, R. S. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J. Clin. Pharmacol., 2005, 45(1), 68-78.
32. Yamazaki, H.; Shibata, A.; Suzuki, M.; Nakajima, M.; Shimada, N.; Guengerich, F. P.; Yokoi, T. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes. Drug Metab. Dispos., 1999, 27(11), 1260-1266.
33. Marill, J.; Cresteil, T.; Lanotte, M.; Chabot, G. G. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol. Pharmacol., 2000, 58(6), 1341-1348.
34. Marill, J.; Capron, C. C.; Idres, N.; Chabot, G. G. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem. Pharmacol., 2002, 63(5), 933-943.
35. Wester, M. R.; Johnson, E. F.; Marques-Soares, C.; Dansette, P. M.; Mansuy, D.; Stout, C. D. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: evidence for multiple substrate binding modes. Biochemistry, 2003, 42(21), 6370-6379.
36. Wester, M. R.; Johnson, E. F.; Marques-Soares, C.; Dijols, S.; Dansette, P. M.; Mansuy, D.; Stout, C. D. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 Å resolution: evidence for an induced fit model of substrate binding. Biochemistry, 2003, 42(31), 9335-9345.
37. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. J. Biol. Chem., 2004, 279(34), 35630-35637.
38. Ridderstrom, M.; Masimirembwa, C.; Trump-Kallmeyer, S.; Ahlefelt, M.; Otter, C.; Andersson, T. B. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem. Biophys. Res. Commun., 2000, 270(3), 983-987.
39. Davies, C.; Witham, K.; Scott, J. R.; Pearson, A.; DeVoss, J. J.; Graham, S. E.; Gillam, E. M. Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9). Drug Metab. Dispos., 2004, 32(4), 431-436.
40. Rahman, A.; Korzekwa, K. R.; Grogan, J.; Gonzalez, F. J.; Harris, J. W. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 1994, 54(21), 5543-5546.
41. Harris, J. W.; Rahman, A.; Kim, B. R.; Guengerich, F. P.; Collins, J. M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 1994, 54(15), 4026-4035.
42. Cresteil, T.; Monsarrat, B.; Dubois, J.; Sonnier, M.; Alvinerie, P.; Gueritte, F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab. Dispos., 2002, 30(4), 438-445.
43. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature, 1979, 277(5698), 665-667.
44. Sonnichsen, D. S.; Liu, Q.; Schuetz, E. G.; Schuetz, J. D.; Pappo, A.; Relling, M. V. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther., 1995, 275(2), 566-575.
45. Kumar, G. N.; Walle, U. K.; Walle, T. Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J. Pharmacol. Exp. Ther., 1994, 268(3), 1160-1165.
46. Cresteil, T.; Monsarrat, B.; Alvinerie, P.; Treluyer, J. M.; Vieira, I.; Wright, M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res., 1994, 54(2), 386-392.
47. Monsarrat, B.; Chatelut, E.; Royer, I.; Alvinerie, P.; Dubois, J.; Dezeuse, A.; Roche, H.; Cros, S.; Wright, M.; Canal, P. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab. Dispos., 1998, 26(3), 229-233.
48. Gianni, L.; Kearns, C. M.; Giani, A.; Capri, G.; Vigano, L.; Lacatelli, A.; Bonadonna, G.; Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 1995, 13(1), 180-190.
49. Churchill, F. C.; Patchen, L. C.; Campbell, C. C.; Schwartz, I. K.; Nguyen-Dinh, P.; Dickinson, C. M. Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life Sci., 1985, 36(1), 53-62.
50. Churchill, F. C.; Mount, D. L.; Patchen, L. C.; Bjorkman, A. Isolation, characterization and standardization of a major metabolite of amodiaquine by chromatographic and spectroscopic methods. J. Chromatogr., 1986, 377, 307-318.
51. Mount, D. L.; Patchen, L. C.; Nguyen-Dinh, P.; Barber, A. M.; Schwartz, I. K.; Churchill, F. C. Sensitive analysis of blood for amodiaquine and three metabolites by high-performance liquid chromatography with electrochemical detection. J. Chromatogr., 1986, 383(2), 375-386.
52. Winstanley, P. A.; Edwards, G.; Orme, M. L.; Breckenridge, A. M. Effect of dose size on amodiaquine pharmacokinetics after oral administration. Eur. J. Clin. Pharmacol., 1987, 33(3), 331-333.
53. Laurent, F.; Saivin, S.; Chretien, P.; Magnaval, J. F.; Peyron, F.; Sqalli, A.; Tufenkji, A. E.; Coulais, Y.; Baba, H.; Campistron, G. Pharmacokinetic and pharmacodynamic study of amodiaquine and its two metabolites after a single oral dose in human volunteers. Arzneimittelforschung, 1993, 43(5), 612-616.
54. Huang, S. M.; Strong, J. M.; Zhang, L.; Reynolds, K. S.; Nallani, S.; Temple, R.; Abraham, S.; Habet, S. A.; Baweja, R. K.; Burckart, G. J.; Chung, S.; Colangelo, P.; Frucht, D.; Green, M. D.; Hepp, P.; Karnaukhova, E.; Ko, H. S.; Lee, J. I.; Marroum, P. J.; Norden, J. M.; Qiu, W.; Rahman, A.; Sobel, S.; Stifano, T.; Thummel, K.; Wei, X. X.; Yasuda, S.; Zheng, J. H.; Zhao, H.; Lesko, L. J. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol., 2008, 48(6), 662-670.
55. Huang, S. M.; Temple, R.; Throckmorton, D. C.; Lesko, L. J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther., 2007, 81(2), 298-304.
56. Ong, C. E.; Coulter, S.; Birkett, D. J.; Bhasker, C. R.; Miners, J. O. The xenobiotic inhibitor profile of cytochrome P4502C8. Br. J. Clin. Pharmacol., 2000, 50(6), 573-580.
57. Bidstrup, T. B.; Bjornsdottir, I.; Sidelmann, U. G.; Thomsen, M. S.; Hansen, K. T. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br. J. Clin. Pharmacol., 2003, 56(3), 305-314.
58. Niemi, M.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia, 2003, 46(3), 347-351.
59. Tornio, A.; Niemi, M.; Neuvonen, M.; Laitila, J.; Kalliokoski, A.; Neuvonen, P. J.; Backman, J. T. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin. Pharmacol. Ther., 2008, 84(3), 403-411.
60. Cox, P. J.; Ryan, D. A.; Hollis, F. J.; Harris, A. M.; Miller, A. K.; Vousden, M.; Cowley, H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos., 2000, 28(7), 772-780.
61. Baldwin, S. J.; Clarke, S. E.; Chenery, R. J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br. J. Clin. Pharmacol., 1999, 48(3), 424-432.
62. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPARγ). J. Biol. Chem., 1995, 270(22), 12953-12956.
63. Tornio, A.; Niemi, M.; Neuvonen, P. J.; Backman, J. T. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab. Dispos., 2008, 36(1), 73-80.
64. Kajosaari, L. I.; Jaakkola, T.; Neuvonen, P. J.; Backman, J. T. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur. J. Clin. Pharmacol., 2006, 62(3), 217-223.
65. Jaakkola, T.; Laitila, J.; Neuvonen, P. J.; Backman, J. T. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin. Pharmacol. Toxicol., 2006, 99(1), 44-51.
66. Zhong, W. Z.; Williams, M. G. Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction. J. Pharm. Biomed. Anal., 1996, 14(4), 465-473.
67. Christensen, M. L.; Meibohm, B.; Capparelli, E. V.; Velasquez-Mieyer, P.; Burghen, G. A.; Tamborlane, W. V. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J. Clin. Pharmacol., 2005, 45(10), 1137-1144.
68. Tanis, S. P.; Parker, T. T.; Colca, J. R.; Fisher, R. M.; Kletzein, R. F. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. J. Med. Chem., 1996, 39(26), 5053-5063.
69. Pfutzner, A.; Schneider, C. A.; Forst, T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev. Cardiovasc. Ther., 2006, 4(4), 445-459.
70. Niemi, M.; Backman, J. T.; Kajosaari, L. I.; Leathart, J. B.; Neuvonen, M.; Daly, A. K.; Eichelbaum, M.; Kivisto, K. T.; Neuvonen, P. J. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther., 2005, 77(6), 468-478.
71. Kalliokoski, A.; Neuvonen, M.; Neuvonen, P. J.; Niemi, M. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br. J. Clin. Pharmacol., 2008, 65(1), 78-86.
72. Aquilante, C. L.; Bushman, L. R.; Knutsen, S. D.; Burt, L. E.; Rome, L. C.; Kosmiski, L. A. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum. Genomics, 2008, 3(1), 7-16.
73. Martinez, C.; Garcia-Martin, E.; Blanco, G.; Gamito, F. J.; Ladero, J. M.; Agundez, J. A. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br. J. Clin. Pharmacol., 2005, 59(1), 62-69.
74. Hamman, M. A.; Thompson, G. A.; Hall, S. D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharmacol., 1997, 54(1), 33-41.
75. Kim, K. A.; Park, J. Y.; Lee, J. S.; Lim, S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch. Pharm. Res., 2003, 26(8), 631-637.
76. Wang, J. S.; Neuvonen, M.; Wen, X.; Backman, J. T.; Neuvonen, P. J. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos., 2002, 30(12), 1352-1356.
77. Jacobsen, W.; Kuhn, B.; Soldner, A.; Kirchner, G.; Sewing, K. F.; Kollman, P. A.; Benet, L. Z.; Christians, U. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos., 2000, 28(11), 1369-1378.
78. Prueksaritanont, T.; Ma, B.; Yu, N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol., 2003, 56(1), 120-124.
79. Projean, D.; Morin, P. E.; Tu, T. M.; Ducharme, J. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica, 2003, 33(8), 841-854.
80. Wang, J. S.; DeVane, C. L. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos., 2003, 31(6), 742-747.
81. Kim, K. A.; Chung, J.; Jung, D. H.; Park, J. Y. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur. J. Clin. Pharmacol., 2004, 60(8), 575-581.
82. Kajosaari, L. I.; Laitila, J.; Neuvonen, P. J.; Backman, J. T. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin. Pharmacol. Toxicol., 2005, 97(4), 249-256.
83. Kumar, S.; Samuel, K.; Subramanian, R.; Braun, M. P.; Stearns, R. A.; Chiu, S. H.; Evans, D. C.; Baillie, T. A. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J. Pharmacol. Exp. Ther., 2002, 303(3), 969-978.
84. Delaforge, M.; Pruvost, A.; Perrin, L.; Andre, F. Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17β-glucuronide oxidation to 2-hydroxy-estradiol-17β- glucuronide by CYP2C8. Drug Metab. Dispos., 2005, 33(3), 466-473.
85. Kulling, S. E.; Lehmann, L.; Metzler, M. Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 777(1-2), 211-218.
86. Hu, M.; Krausz, K.; Chen, J.; Ge, X.; Li, J.; Gelboin, H. L.; Gonzalez, F. J. Identification of CYP1A2 as the main isoform for the Phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab. Dispos., 2003, 31(7), 924-931.
87. Miyazawa, M.; Shindo, M.; Shimada, T. Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Drug Metab. Dispos., 2002, 30(5), 602-607.
88. Miyazawa, M.; Shindo, M.; Shimada, T. Sex differences in the metabolism of (+)- and (-)-limonene enantiomers to carveol and perillyl alcohol derivatives by cytochrome P450 enzymes in rat liver microsomes. Chem. Res. Toxicol., 2002, 15(1), 15-20.
89. Spink, D. C.; Eugster, H. P.; Lincoln, D. W., 2nd; Schuetz, J. D.; Schuetz, E. G.; Johnson, J. A.; Kaminsky, L. S.; Gierthy, J. F. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch. Biochem. Biophys., 1992, 293(2), 342-348.
90. Spink, D. C.; Hayes, C. L.; Young, N. R.; Christou, M.; Sutter, T. R.; Jefcoate, C. R.; Gierthy, J. F. The effects of 2,3,7,8-tetrachlorodibenzo-p- dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17β-estradiol 4-hydroxylase. J. Steroid Biochem. Mol. Biol., 1994, 51(5-6), 251-258.
91. Choi, M. H.; Skipper, P. L.; Wishnok, J. S.; Tannenbaum, S. R. Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450. Drug Metab. Dispos., 2005, 33(6), 714-718.
92. Zeldin, D. C.; Moomaw, C. R.; Jesse, N.; Tomer, K. B.; Beetham, J.; Hammock, B. D.; Wu, S. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch. Biochem. Biophys., 1996, 330(1), 87-96.
93. Nadin, L.; Murray, M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem. Pharmacol., 1999, 58(7), 1201-1208.
94. McSorley, L. C.; Daly, A. K. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem. Pharmacol., 2000, 60(4), 517-526.
95. Leo, M. A.; Lasker, J. M.; Raucy, J. L.; Kim, C. I.; Black, M.; Lieber, C. S. Metabolism of retinol and retinoic acid by human liver cytochrome P450 2C8. Arch. Biochem. Biophys., 1989, 269(1), 305-312.
96. White, J. A.; Beckett-Jones, B.; Guo, Y. D.; Dilworth, F. J.; Bonasoro, J.; Jones, G.; Petkovich, M. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J. Biol. Chem., 1997, 272(30), 18538-18541.
97. Ray, W. J.; Bain, G.; Yao, M.; Gottlieb, D. I. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J. Biol. Chem., 1997, 272(30), 18702-18708.
98. Garattini, E.; Gianni, M.; Terao, M. Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr. Pharm. Des., 2007, 13(13), 1375-1400.
99. Gorman, G. S.; Coward, L.; Kerstner-Wood, C.; Cork, L.; Kapetanovic, I. M.; Brouillette, W. J.; Muccio, D. D. In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab. Dispos., 2007, 35(7), 1157-1164.
100. Lasker, J. M.; Chen, W. B.; Wolf, I.; Bloswick, B. P.; Wilson, P. D.; Powell, P. K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of CYP4F2 and CYP4A11. J. Biol. Chem., 2000, 275(6), 4118-4126.
101. Spector, A. A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res., 2009, 50 (Suppl), S52-56.
102. Fisslthaler, B.; Popp, R.; Kiss, L.; Potente, M.; Harder, D. R.; Fleming, I.; Busse, R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 1999, 401(6752), 493-497.
103. Bylund, J.; Kunz, T.; Valmsen, K.; Oliw, E. H. Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J. Pharmacol. Exp. Ther., 1998, 284(1), 51-60.
104. Rifkind, A. B.; Lee, C.; Chang, T. K.; Waxman, D. J. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch. Biochem. Biophys., 1995, 320(2), 380-389.
105. Barbosa-Sicard, E.; Markovic, M.; Honeck, H.; Christ, B.; Muller, D. N.; Schunck, W. H. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem. Biophys. Res. Commun., 2005, 329(4), 1275-1281.
106. Smyth, E. M.; Grosser, T.; Wang, M.; Yu, Y.; FitzGerald, G. A. Prostanoids in health and disease. J. Lipid Res., 2009, 50 (Suppl), S423-428.
107. Zhou, S. F.; Zhou, Z. W.; Yang, L. P.; Cai, J. P. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr. Med. Chem., 2009, 16(27), 3480-3675.
108. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 2002, 34(1-2), 83-448.
109. Veronese, M. E.; Doecke, C. J.; Mackenzie, P. I.; McManus, M. E.; Miners, J. O.; Rees, D. L.; Gasser, R.; Meyer, U. A.; Birkett, D. J. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem. J., 1993, 289(Pt 2), 533-538.
110. Mancy, A.; Antignac, M.; Minoletti, C.; Dijols, S.; Mouries, V.; Duong, N. T.; Battioni, P.; Dansette, P. M.; Mansuy, D. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry, 1999, 38(43), 14264-14270.
111. Minoletti, C.; Dijols, S.; Dansette, P. M.; Mansuy, D. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP2C18. Biochemistry, 1999, 38(24), 7828-7836.
112. Zhou, S.; Chan, E.; Li, X.; Huang, M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther. Clin. Risk Manag., 2005, 1(1), 3-13.
113. Zhou, S.; Chan, E.; Lim, L. Y.; Boelsterli, U. A.; Li, S. C.; Wang, J.; Zhang, Q.; Huang, M.; Xu, A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab., 2004, 5(5), 415-442.
114. Zhou, S.; Yung Chan, S.; Cher Goh, B.; Chan, E.; Duan, W.; Huang, M.; McLeod, H. L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 2005, 44(3), 279-304.
115. Zhou, S. F.; Xue, C. C.; Yu, X. Q.; Li, C.; Wang, G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit., 2007, 29(6), 687-710.
116. Polasek, T. M.; Elliot, D. J.; Lewis, B. C.; Miners, J. O. Mechanism-based inactivation of human cytochrome P450 2C8 by drugs in vitro. J. Pharmacol. Exp. Ther., 2004, 311(3), 996-1007.
117. Ohyama, K.; Nakajima, M.; Suzuki, M.; Shimada, N.; Yamazaki, H.; Yokoi, T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol., 2000, 49(3), 244-253.
118. Ogilvie, B. W.; Zhang, D.; Li, W.; Rodrigues, A. D.; Gipson, A. E.; Holsapple, J.; Toren, P.; Parkinson, A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos., 2006, 34(1), 191-197.
119. Backman, J. T.; Honkalammi, J.; Neuvonen, M.; Kurkinen, K. J.; Tornio, A.; Niemi, M.; Neuvonen, P. J. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab. Dispos., 2009, 27(12), 2359-2366.
120. Walsky, R. L.; Obach, R. S.; Gaman, E. A.; Gleeson, J. P.; Proctor, W. R. Selective inhibition of human cytochrome P450 2C8 by montelukast. Drug Metab. Dispos., 2005, 33(3), 413-418.
121. Kajosaari, L. I.; Niemi, M.; Backman, J. T.; Neuvonen, P. J. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin. Pharmacol. Ther., 2006, 79(3), 231-242.
122. Jaakkola, T.; Backman, J. T.; Neuvonen, M.; Niemi, M.; Neuvonen, P. J. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur. J. Clin. Pharmacol., 2006, 62(7), 503-509.
123. Desai, P. B.; Duan, J. Z.; Zhu, Y. W.; Kouzi, S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur. J. Drug Metab. Pharmacokinet., 1998, 23(3), 417-424.
124. Ghosal, A.; Chowdhury, S. K.; Tong, W.; Hapangama, N.; Yuan, Y.; Su, A. D.; Zbaida, S. Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab. Dispos., 2006, 34(4), 628-635.
125. Bun, S. S.; Ciccolini, J.; Bun, H.; Aubert, C.; Catalin, J. Drug interactions of paclitaxel metabolism in human liver microsomes. J. Chemother., 2003, 15(3), 266-274.
126. Obach, R. S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther., 2000, 294(1), 88-95.
127. Kim, K. A.; Park, P. W.; Kim, H. K.; Ha, J. M.; Park, J. Y. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J. Clin. Pharmacol., 2005, 45(8), 941-946.
128. Mancy, A.; Dijols, S.; Poli, S.; Guengerich, P.; Mansuy, D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate bind ing site topology of CYP2C9. Biochemistry, 1996, 35(50), 16205-16212.
129. Wen, X.; Wang, J. S.; Backman, J. T.; Laitila, J.; Neuvonen, P. J. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos., 2002, 30(6), 631-635.
130. Niemi, M.; Kajosaari, L. I.; Neuvonen, M.; Backman, J. T.; Neuvonen, P. J. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br. J. Clin. Pharmacol., 2004, 57(4), 441-447.
131. Wen, X.; Wang, J. S.; Backman, J. T.; Kivisto, K. T.; Neuvonen, P. J. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos., 2001, 29(11), 1359-1361.
132. Lilja, J. J.; Backman, J. T.; Neuvonen, P. J. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br. J. Clin. Pharmacol., 2005, 59(4), 433-439.
133. Shitara, Y.; Hirano, M.; Sato, H.; Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther., 2004, 311(1), 228-236.
134. Tornio, A.; Pasanen, M. K.; Laitila, J.; Neuvonen, P. J.; Backman, J. T. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin. Pharmacol. Toxicol., 2005, 97(2), 104-108.
135. Hatorp, V.; Hansen, K. T.; Thomsen, M. S. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J. Clin. Pharmacol., 2003, 43(6), 649-660.
136. Yamazaki, H.; Suzuki, M.; Tane, K.; Shimada, N.; Nakajima, M.; Yokoi, T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica, 2000, 30(1), 61-70.
137. Sahi, J.; Black, C. B.; Hamilton, G. A.; Zheng, X.; Jolley, S.; Rose, K. A.; Gilbert, D.; LeCluyse, E. L.; Sinz, M. W. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab. Dispos., 2003, 31(4), 439-446.
138. Chang, T. K.; Gonzalez, F. J.; Waxman, D. J. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys., 1994, 311(2), 437-442.
139. Vuppugalla, R.; Chang, S. Y.; Zhang, H.; Marathe, P. H.; Rodrigues, D. A. Effect of commonly used organic solvents on the kinetics of cytochrome P450 2B6- and 2C8-dependent activity in human liver microsomes. Drug Metab. Dispos., 2007, 35(11), 1990-1995.
140. O'Donnell, C. J.; Grime, K.; Courtney, P.; Slee, D.; Riley, R. J. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting. Drug Metab. Dispos., 2007, 35(3), 381-385.
141. Dresser, G. K.; Spence, J. D.; Bailey, D. G. Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet., 2000, 38(1), 41-57.
142. Mullins, M. E.; Horowitz, B. Z.; Linden, D. H.; Smith, G. W.; Norton, R. L.; Stump, J. Life-threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers. JAMA, 1998, 280(2), 157-158.
143. Pedersen, R. S.; Damkier, P.; Brosen, K. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br. J. Clin. Pharmacol., 2006, 62(6), 682-689.
144. Niemi, M.; Backman, J. T.; Granfors, M.; Laitila, J.; Neuvonen, M.; Neuvonen, P. J. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia, 2003, 46(10), 1319-1323.
145. Jaakkola, T.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin. Pharmacol. Ther., 2005, 77(5), 404-414.
146. Tornio, A.; Niemi, M.; Neuvonen, P. J.; Backman, J. T. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. Eur. J. Clin. Pharmacol., 2007, 63(5), 463-469.
147. Backman, J. T.; Kyrklund, C.; Neuvonen, M.; Neuvonen, P. J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther., 2002, 72(6), 685-691.
148. Niemi, M.; Tornio, A.; Pasanen, M. K.; Fredrikson, H.; Neuvonen, P. J.; Backman, J. T. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur. J. Clin. Pharmacol., 2006, 62(6), 463-472.
149. Farmer, J. A. Learning from the cerivastatin experience. Lancet, 2001, 358(9291), 1383-1385.
150. Kajosaari, L. I.; Backman, J. T.; Neuvonen, M.; Laitila, J.; Neuvonen, P. J. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br. J. Clin. Pharmacol., 2004, 58(4), 390-396.
151. Shek, A.; Ferrill, M. J. Statin-fibrate combination therapy. Ann. Pharmacother., 2001, 35(7-8), 908-917.
152. Kyrklund, C.; Backman, J. T.; Kivisto, K. T.; Neuvonen, M.; Laitila, J.; Neuvonen, P. J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther., 2001, 69(5), 340-345.
153. Wen, X.; Wang, J. S.; Neuvonen, P. J.; Backman, J. T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol., 2002, 57(11), 799-804.
154. Yew, W. W. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf., 2002, 25(2), 111-133.
155. Chen, D.; Lepar, G.; Kemper, B. A transcriptional regulatory element common to a large family of hepatic cytochrome P450 genes is a functional binding site of the orphan receptor HNF-4. J. Biol. Chem., 1994, 269(7), 5420-5427.
156. Madan, A.; Graham, R. A.; Carroll, K. M.; Mudra, D. R.; Burton, L. A.; Krueger, L. A.; Downey, A. D.; Czerwinski, M.; Forster, J.; Ribadeneira, M. D.; Gan, L. S.; LeCluyse, E. L.; Zech, K.; Robertson, P., Jr.; Koch, P.; Antonian, L.; Wagner, G.; Yu, L.; Parkinson, A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos., 2003, 31(4), 421-431.
157. Gerbal-Chaloin, S.; Pascussi, J. M.; Pichard-Garcia, L.; Daujat, M.; Waechter, F.; Fabre, J. M.; Carrere, N.; Maurel, P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos., 2001, 29(3), 242-251.
158. Raucy, J. L.; Mueller, L.; Duan, K.; Allen, S. W.; Strom, S.; Lasker, J. M. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J. Pharmacol. Exp. Ther., 2002, 302(2), 475-482.
159. Ferguson, S. S.; Chen, Y.; LeCluyse, E. L.; Negishi, M.; Goldstein, J. A. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4α. Mol. Pharmacol., 2005, 68(3), 747-757.
160. Maglich, J. M.; Parks, D. J.; Moore, L. B.; Collins, J. L.; Goodwin, B.; Billin, A. N.; Stoltz, C. A.; Kliewer, S. A.; Lambert, M. H.; Willson, T. M.; Moore, J. T. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem., 2003, 278(19), 17277-17283.
161. Edwards, R. J.; Price, R. J.; Watts, P. S.; Renwick, A. B.; Tredger, J. M.; Boobis, A. R.; Lake, B. G. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos., 2003, 31(3), 282-288.
162. Moore, L. B.; Parks, D. J.; Jones, S. A.; Bledsoe, R. K.; Consler, T. G.; Stimmel, J. B.; Goodwin, B.; Liddle, C.; Blanchard, S. G.; Willson, T. M.; Collins, J. L.; Kliewer, S. A. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem., 2000, 275(20), 15122-15127.
163. Ged, C.; Beaune, P. Isolation of the human cytochrome P-450 IIC8 gene: multiple glucocorticoid responsive elements in the 5′ region. Biochim. Biophys. Acta, 1991, 1088(3), 433-435.
164. Strausberg, R. L.; Feingold, E. A.; Grouse, L. H.; Derge, J. G.; Klausner, R. D.; Collins, F. S.; Wagner, L.; Shenmen, C. M.; Schuler, G. D.; Altschul, S. F.; Zeeberg, B.; Buetow, K. H.; Schae fer, C. F.; Bhat, N. K.; Hopkins, R. F.; Jordan, H.; Moore, T.; Max, S. I.; Wang, J.; Hsieh, F.; Diatchenko, L.; Marusina, K.; Farmer, A. A.; Rubin, G. M.; Hong, L.; Stapleton, M.; Soares, M. B.; Bonaldo, M. F.; Casavant, T. L.; Scheetz, T. E.; Brownstein, M. J.; Usdin, T. B.; Toshiyuki, S.; Carninci, P.; Prange, C.; Raha, S. S.; Loquellano, N. A.; Peters, G. J.; Abramson, R. D.; Mullahy, S. J.; Bosak, S. A.; McEwan, P. J.; McKernan, K. J.; Malek, J. A.; Gunaratne, P. H.; Richards, S.; Worley, K. C.; Hale, S.; Garcia, A. M.; Gay, L. J.; Hulyk, S. W.; Villalon, D. K.; Muzny, D. M.; Sodergren, E. J.; Lu, X.; Gibbs, R. A.; Fahey, J.; Helton, E.; Ketteman, M.; Madan, A.; Rodrigues, S.; Sanchez, A.; Whiting, M.; Young, A. C.; Shevchenko, Y.; Bouffard, G. G.; Blakesley, R. W.; Touchman, J. W.; Green, E. D.; Dickson, M. C.; Rodriguez, A. C.; Grimwood, J.; Schmutz, J.; Myers, R. M.; Butterfield, Y. S.; Krzywinski, M. I.; Skalska, U.; Smailus, D. E.; Schnerch, A.; Schein, J. E.; Jones, S. J.; Marra, M. A. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(26), 16899-16903.
165. Cairns, W.; Smith, C. A.; McLaren, A. W.; Wolf, C. R. Characterization of the human cytochrome P450 2D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J. Biol. Chem., 1996, 271(41), 25269-25276.
166. Bort, R.; Gomez-Lechon, M. J.; Castell, J. V.; Jover, R. Role of hepatocyte nuclear factor-3γ in the expression of human CYP2C genes. Arch. Biochem. Biophys., 2004, 426(1), 63-72.
167. Gerbal-Chaloin, S.; Daujat, M.; Pascussi, J. M.; Pichard-Garcia, L.; Vilarem, M. J.; Maurel, P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem., 2002, 277(1), 209-217.
168. Chen, Y.; Ferguson, S. S.; Negishi, M.; Goldstein, J. A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther., 2004, 308(2), 495-501.
169. Ibeanu, G. C.; Goldstein, J. A. Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry, 1995, 34(25), 8028-8036.
170. Goodwin, B.; Hodgson, E.; Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol., 1999, 56(6), 1329-1339.
171. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem., 2001, 276(18), 14581-14587.
172. Guo, G. L.; Staudinger, J.; Ogura, K.; Klaassen, C. D. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16α-carbonitrile is via interaction with pregnane X receptor. Mol. Pharmacol., 2002, 61(4), 832-839.
173. Tirona, R. G.; Lee, W.; Leake, B. F.; Lan, L. B.; Cline, C. B.; Lamba, V.; Parviz, F.; Duncan, S. A.; Inoue, Y.; Gonzalez, F. J.; Schuetz, E. G.; Kim, R. B. The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med., 2003, 9(2), 220-224.
174. Kostrubsky, V. E.; Lewis, L. D.; Strom, S. C.; Wood, S. G.; Schuetz, E. G.; Schuetz, J. D.; Sinclair, P. R.; Wrighton, S. A.; Sinclair, J. F. Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch. Biochem. Biophys., 1998, 355(2), 131-136.
175. Synold, T. W.; Dussault, I.; Forman, B. M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med., 2001, 7(5), 584-590.
176. Jaakkola, T.; Backman, J. T.; Neuvonen, M.; Laitila, J.; Neuvonen, P. J. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br. J. Clin. Pharmacol., 2006, 61(1), 70-78.
177. Park, J. Y.; Kim, K. A.; Kang, M. H.; Kim, S. L.; Shin, J. G. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin. Pharmacol. Ther., 2004, 75(3), 157-162.
178. Niemi, M.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J.; Kivisto, K. T. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin. Pharmacol. Ther., 2000, 68(5), 495-500.
179. Bidstrup, T. B.; Stilling, N.; Damkier, P.; Scharling, B.; Thomsen, M. S.; Brosen, K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur. J. Clin. Pharmacol., 2004, 60(2), 109-114.
180. Soyama, A.; Hanioka, N.; Saito, Y.; Murayama, N.; Ando, M.; Ozawa, S.; Sawada, J. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol. Toxicol., 2002, 91(4), 174-178.
181. Yasar, U.; Lundgren, S.; Eliasson, E.; Bennet, A.; Wiman, B.; de Faire, U.; Rane, A. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun., 2002, 299(1), 25-28.
182. Nakajima, M.; Fujiki, Y.; Noda, K.; Ohtsuka, H.; Ohkuni, H.; Kyo, S.; Inoue, M.; Kuroiwa, Y.; Yokoi, T. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab. Dispos., 2003, 31(6), 687-690.
183. Ishiguro, A.; Kubota, T.; Ishikawa, H.; Iga, T. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity. Clin. Chim. Acta, 2004, 344(1-2), 201-204.
184. Rodriguez-Antona, C.; Niemi, M.; Backman, J. T.; Kajosaari, L. I.; Neuvonen, P. J.; Robledo, M.; Ingelman-Sundberg, M. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J., 2008, 8(4), 268-277.
185. Solus, J. F.; Arietta, B. J.; Harris, J. R.; Sexton, D. P.; Steward, J. Q.; McMunn, C.; Ihrie, P.; Mehall, J. M.; Edwards, T. L.; Dawson, E. P. Genetic variation in eleven Phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics, 2004, 5(7), 895-931.
186. Daily, E. B.; Aquilante, C. L. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics, 2009, 10(9), 1489-1510.
187. Parikh, S.; Ouedraogo, J. B.; Goldstein, J. A.; Rosenthal, P. J.; Kroetz, D. L. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin. Pharmacol. Ther., 2007, 82(2), 197-203.
188. Boberg, M.; Angerbauer, R.; Fey, P.; Kanhai, W. K.; Karl, W.; Kern, A.; Ploschke, J.; Radtke, M. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab. Dispos., 1997, 25(3), 321-331.
189. Ozaki, H.; Ishikawa, C. T.; Ishii, T.; Toyoda, A.; Murano, T.; Miyashita, Y.; Shirai, K. Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. J. Clin. Pharm. Ther., 2005, 30(2), 189-192.
190. Kirchheiner, J.; Kudlicz, D.; Meisel, C.; Bauer, S.; Meineke, I.; Roots, I.; Brockmoller, J. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther., 2003, 74(2), 186-194.
191. Garcia-Martin, E.; Martinez, C.; Tabares, B.; Frias, J.; Agundez, J. A. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther., 2004, 76(2), 119-127.
192. Nakajima, M.; Fujiki, Y.; Kyo, S.; Kanaya, T.; Nakamura, M.; Maida, Y.; Tanaka, M.; Inoue, M.; Yokoi, T. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J. Clin. Pharmacol., 2005, 45(6), 674-682.
193. Henningsson, A.; Marsh, S.; Loos, W. J.; Karlsson, M. O.; Garsa, A.; Mross, K.; Mielke, S.; Vigano, L.; Locatelli, A.; Verweij, J.; Sparreboom, A.; McLeod, H. L. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res., 2005, 11(22), 8097-8104.
194. Jiko, M.; Yano, I.; Sato, E.; Takahashi, K.; Motohashi, H.; Masuda, S.; Okuda, M.; Ito, N.; Nakamura, E.; Segawa, T.; Kamoto, T.; Ogawa, O.; Inui, K. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int. J. Clin. Oncol., 2007, 12(4), 284-290.
195. Marsh, S.; Somlo, G.; Li, X.; Frankel, P.; King, C. R.; Shannon, W. D.; McLeod, H. L.; Synold, T. W. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J., 2007, 7(5), 362-365.
196. Niemi, M.; Leathart, J. B.; Neuvonen, M.; Backman, J. T.; Daly, A. K.; Neuvonen, P. J. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther., 2003, 74(4), 380-387.
197. Bidstrup, T. B.; Damkier, P.; Olsen, A. K.; Ekblom, M.; Karlsson, A.; Brosen, K. The impact of CYP2C8 polymorphism and grape-fruit juice on the pharmacokinetics of repaglinide. Br. J. Clin. Pharmacol., 2006, 61(1), 49-57.
198. Kalliokoski, A.; Neuvonen, M.; Neuvonen, P. J.; Niemi, M. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br. J. Clin. Pharmacol., 2008, 66(6), 818-825.
199. Kirchheiner, J.; Meineke, I.; Fuhr, U.; Rodriguez-Antona, C.; Lebedeva, E.; Brockmoller, J. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics, 2008, 9(3), 277-288.
200. Kirchheiner, J.; Thomas, S.; Bauer, S.; Tomalik-Scharte, D.; Hering, U.; Doroshyenko, O.; Jetter, A.; Stehle, S.; Tsahuridu, M.; Meineke, I.; Brockmoller, J.; Fuhr, U. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther., 2006, 80(6), 657-667.
201. Kostrubsky, V. E.; Sinclair, J. F.; Ramachandran, V.; Venkataramanan, R.; Wen, Y. H.; Kindt, E.; Galchev, V.; Rose, K.; Sinz, M.; Strom, S. C. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab. Dispos., 2000, 28(10), 1192-1197.
202. Loi, C. M.; Young, M.; Randinitis, E.; Vassos, A.; Koup, J. R. Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet., 1999, 37(2), 91-104.
203. Lofgren, S.; Baldwin, R. M.; Hiratsuka, M.; Lindqvist, A.; Carlberg, A.; Sim, S. C.; Schulke, M.; Snait, M.; Edenro, A.; Fransson-Steen, R.; Terelius, Y.; Ingelman-Sundberg, M. Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression. Drug Metab. Dispos., 2008, 36(5), 955-962.
204. Theken, K. N.; Lee, C. R. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics, 2007, 8(10), 1369-1383.
205. Lundblad, M. S.; Stark, K.; Eliasson, E.; Oliw, E.; Rane, A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem. Biophys. Res. Commun., 2005, 327(4), 1052-1057.
206. Yasar, U.; Bennet, A. M.; Eliasson, E.; Lundgren, S.; Wiman, B.; De Faire, U.; Rane, A. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics, 2003, 13(12), 715-720.
207. King, L. M.; Gainer, J. V.; David, G. L.; Dai, D.; Goldstein, J. A.; Brown, N. J.; Zeldin, D. C. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet. Genomics, 2005, 15(1), 7-13.
208. Dreisbach, A. W.; Japa, S.; Sigel, A.; Parenti, M. B.; Hess, A. E.; Srinouanprachanh, S. L.; Rettie, A. E.; Kim, H.; Farin, F. M.; Hamm, L. L.; Lertora, J. J. The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am. J. Hypertens., 2005, 18(10), 1276-1281.
209. Watanabe, K.; Yamaori, S.; Funahashi, T.; Kimura, T.; Yamamoto, I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci., 2007, 80(15), 1415-1419.
210. Salva, M.; Jansat, J. M.; Martinez-Tobed, A.; Palacios, J. M. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab. Dispos., 2003, 31(4), 404-411.
211. Niwa, T.; Sato, R.; Yabusaki, Y.; Ishibashi, F.; Katagiri, M. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica, 1999, 29(2), 187-193.
212. Ohyama, K.; Nakajima, M.; Nakamura, S.; Shimada, N.; Yamazaki, H.; Yokoi, T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab. Dispos., 2000, 28(11), 1303-1310.
213. Venkatakrishnan, K.; von Moltke, L. L.; Greenblatt, D. J. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther., 2001, 297(1), 326-337.
214. Engel, G.; Hofmann, U.; Heidemann, H.; Cosme, J.; Eichelbaum, M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3- hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther., 1996, 59(6), 613-623.
215. Grace, J. M.; Skanchy, D. J.; Aguilar, A. J. Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A. Xenobiotica, 1999, 29(7), 703-717.
216. Nakajima, M.; Nakamura, S.; Tokudome, S.; Shimada, N.; Yamazaki, H.; Yokoi, T. Azelastine N-demethylation by CYP3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab. Dispos., 1999, 27(12), 1381-1391.
217. Hanna, I. H.; Krauser, J. A.; Cai, H.; Kim, M. S.; Guengerich, F. P. Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. J. Biol. Chem., 2001, 276(43), 39553-39561.
218. Picard, N.; Cresteil, T.; Djebli, N.; Marquet, P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos., 2005, 33(5), 689-695.
219. Gu, L.; Gonzalez, F. J.; Kalow, W.; Tang, B. K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics, 1992, 2(2), 73-77.
220. Eugster, H. P.; Probst, M.; Wurgler, F. E.; Sengstag, C. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab. Dispos., 1993, 21(1), 43-49.
221. Fuhr, U.; Doehmer, J.; Battula, N.; Wolfel, C.; Kudla, C.; Keita, Y.; Staib, A. H. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol., 1992, 43(2), 225-235.
222. Ha, H. R.; Chen, J.; Krahenbuhl, S.; Follath, F. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur. J. Clin. Pharmacol., 1996, 49(4), 309-315.
223. Kot, M.; Daniel, W. A. The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochem. Pharmacol., 2008, 76(4), 543-551.
224. Kerr, B. M.; Thummel, K. E.; Wurden, C. J.; Klein, S. M.; Kroetz, D. L.; Gonzalez, F. J.; Levy, R. H. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol., 1994, 47(11), 1969-1979.
225. Desta, Z.; Soukhova, N.; Mahal, S. K.; Flockhart, D. A. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab. Dispos., 2000, 28(7), 789-800.
226. Desta, Z.; Soukhova, N.; Morocho, A. M.; Flockhart, D. A. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J. Pharmacol. Exp. Ther., 2001, 298(2), 508-520.
227. Linnet, K.; Olesen, O. V. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab. Dispos., 1997, 25(12), 1379-1382.
228. Eiermann, B.; Engel, G.; Johansson, I.; Zanger, U. M.; Bertilsson, L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br. J. Clin. Pharmacol., 1997, 44(5), 439-446.
229. Fang, J.; Coutts, R. T.; McKenna, K. F.; Baker, G. B. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch. Pharmacol., 1998, 358(5), 592-599.
230. Tugnait, M.; Hawes, E. M.; McKay, G.; Eichelbaum, M.; Midha, K. K. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem. Biol. Interact., 1999, 118(2), 171-189.
231. Olesen, O. V.; Linnet, K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J. Clin. Pharmacol., 2001, 41(8), 823-832.
232. Ma, B.; Subramanian, R.; Schrag, M. L.; Rodrigues, A. D.; Tang, C. Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes. Drug Metab. Dispos., 2004, 32(5), 473-478.
233. Chang, T. K.; Weber, G. F.; Crespi, C. L.; Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 1993, 53(23), 5629-5637.
234. Ren, S.; Yang, J. S.; Kalhorn, T. F.; Slattery, J. T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res., 1997, 57(19), 4229-4235.
235. Chen, C. S.; Lin, J. T.; Goss, K. A.; He, Y. A.; Halpert, J. R.; Waxman, D. J. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol. Pharmacol., 2004, 65(5), 1278-1285.
236. Huang, Z.; Roy, P.; Waxman, D. J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol., 2000, 59(8), 961-972.
237. Code, E. L.; Crespi, C. L.; Penman, B. W.; Gonzalez, F. J.; Chang, T. K.; Waxman, D. J. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos., 1997, 25(8), 985-993.
238. Yu, L.; Waxman, D. J. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab. Dispos., 1996, 24(11), 1254-1262.
239. Winter, H. R.; Wang, Y.; Unadkat, J. D. CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab. Dispos., 2000, 28(8), 865-868.
240. Ono, S.; Hatanaka, T.; Miyazawa, S.; Tsutsui, M.; Aoyama, T.; Gonzalez, F. J.; Satoh, T. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica, 1996, 26(11), 1155-1166.
241. Molden, E.; Asberg, A.; Christensen, H. CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells. Eur. J. Clin. Pharmacol., 2000, 56(8), 575-579.
242. Jones, D. R.; Gorski, J. C.; Hamman, M. A.; Mayhew, B. S.; Rider, S.; Hall, S. D. Diltiazem inhibition of cytochrome P450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther., 1999, 290(3), 1116-1125.
243. Evans, D. C.; O'Connor, D.; Lake, B. G.; Evers, R.; Allen, C.; Hargreaves, R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab. Dispos., 2003, 31(7), 861-869.
244. Ling, J.; Johnson, K. A.; Miao, Z.; Rakhit, A.; Pantze, M. P.; Hamilton, M.; Lum, B. L.; Prakash, C. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab. Dispos., 2006, 34(3), 420-426.
245. Tougou, K.; Gotou, H.; Ohno, Y.; Nakamura, A. Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica, 2004, 34(5), 449-461.
246. Suzuki, A.; Iida, I.; Tanaka, F.; Akimoto, M.; Fukushima, K.; Tani, M.; Ishizaki, T.; Chiba, K. Identification of human cytochrome P450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab. Dispos., 1999, 27(11), 1254-1259.
247. Elliot, D. J.; Suharjono; Lewis, B. C.; Gillam, E. M.; Birkett, D. J.; Gross, A. S.; Miners, J. O. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br. J. Clin. Pharmacol., 2007, 64(4), 450-457.
248. Halliday, R. C.; Jones, B. C.; Smith, D. A.; Kitteringham, N. R.; Park, B. K. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br. J. Clin. Pharmacol., 1995, 40(4), 369-378.
249. Granvil, C. P.; Madan, A.; Sharkawi, M.; Parkinson, A.; Wainer, I. W. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab. Dispos., 1999, 27(4), 533-541.
250. 1D receptor agonist. Xenobiotica, 2000, 30(1), 47-59.
251. Pearce, R. E.; Rodrigues, A. D.; Goldstein, J. A.; Parkinson, A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther., 1996, 277(2), 805-816.
252. Kim, K. A.; Kim, M. J.; Park, J. Y.; Shon, J. H.; Yoon, Y. R.; Lee, S. S.; Liu, K. H.; Chun, J. H.; Hyun, M. H.; Shin, J. G. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab. Dispos., 2003, 31(10), 1227-1234.
253. Albrecht, W.; Unger, A.; Nussler, A. K.; Laufer, S. In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl ] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase. Drug Metab. Dispos., 2008, 36(5), 894-903.
254. Imaoka, S.; Enomoto, K.; Oda, Y.; Asada, A.; Fujimori, M.; Shimada, T.; Fujita, S.; Guengerich, F. P.; Funae, Y. Lidocaine metabolism by human cytochrome P450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P450s. J. Pharmacol. Exp. Ther., 1990, 255(3), 1385-1391.
255. Bargetzi, M. J.; Aoyama, T.; Gonzalez, F. J.; Meyer, U. A. Lidocaine metabolism in human liver microsomes by cytochrome P450 3A4. Clin. Pharmacol. Ther., 1989, 46(5), 521-527.
256. Stormer, E.; von Moltke, L. L.; Shader, R. I.; Greenblatt, D. J. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P450 1A2, 2D6, and 3A4. Drug Metab. Dispos., 2000, 28(10), 1168-1175.
257. Miners, J. O.; Coulter, S.; Tukey, R. H.; Veronese, M. E.; Birkett, D. J. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem. Pharmacol., 1996, 51(8), 1003-1008.
258. 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab. Dispos., 1996, 24(1), 126-136.
259. Tracy, T. S.; Marra, C.; Wrighton, S. A.; Gonzalez, F. J.; Korzekwa, K. R. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur. J. Clin. Pharmacol., 1997, 52(4), 293-298.
260. Dicke, K. E.; Skrlin, S. M.; Murphy, S. E. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab. Dispos., 2005, 33(12), 1760-1764.
261. Yamazaki, H.; Inoue, K.; Hashimoto, M.; Shimada, T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol., 1999, 73(2), 65-70.
262. Busse, D.; Cosme, J.; Beaune, P.; Kroemer, H. K.; Eichelbaum, M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch. Pharmacol., 1995, 353(1), 116-121.
263. Tracy, T. S.; Korzekwa, K. R.; Gonzalez, F. J.; Wainer, I. W. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br. J. Clin. Pharmacol., 1999, 47(5), 545-552.
264. Karam, W. G.; Goldstein, J. A.; Lasker, J. M.; Ghanayem, B. I. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos., 1996, 24(10), 1081-1087.
265. Olesen, O. V.; Linnet, K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br. J. Clin. Pharmacol., 2000, 50(6), 563-571.
266. Bajpai, M.; Roskos, L. K.; Shen, D. D.; Levy, R. H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos., 1996, 24(12), 1401-1403.
267. Guitton, J.; Buronfosse, T.; Desage, M.; Flinois, J. P.; Perdrix, J. P.; Brazier, J. L.; Beaune, P. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br. J. Anaesth., 1998, 80(6), 788-795.
268. Hermans, J. J.; Thijssen, H. H. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br. J. Pharmacol., 1993, 110(1), 482-490.
269. Kaminsky, L. S.; Zhang, Z. Y. Human P450 metabolism of warfarin. Pharmacol. Ther., 1997, 73(1), 67-74.
270. Salonen, J. S.; Nyman, L.; Boobis, A. R.; Edwards, R. J.; Watts, P.; Lake, B. G.; Price, R. J.; Renwick, A. B.; Gomez-Lechon, M. J.; Castell, J. V.; Ingelman-Sundberg, M.; Hidestrand, M.; Guillouzo, A.; Corcos, L.; Goldfarb, P. S.; Lewis, D. F.; Taavitsainen, P.; Pelkonen, O. Comparative studies on the cytochrome P450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Dispos., 2003, 31(9), 1093-1102.
271. Hidestrand, M.; Oscarson, M.; Salonen, J. S.; Nyman, L.; Pelkonen, O.; Turpeinen, M.; Ingelman-Sundberg, M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos., 2001, 29(11), 1480-1484.
272. Grace, J. M.; Kinter, M. T.; Macdonald, T. L. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl- Npropynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol., 1994, 7(3), 286-290.
273. Kamada, T.; Chow, T.; Hiroi, T.; Imaoka, S.; Morimoto, K.; Ohde, H.; Funae, Y. Metabolism of selegiline hydrochloride, a selective monoamine B-type inhibitor, in human liver microsomes. Drug Metab. Pharmacokinet., 2002, 17(3), 199-206.
274. Kumar, G. N.; Dubberke, E.; Rodrigues, A. D.; Roberts, E.; Dennisen, J. F. Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab. Dispos., 1997, 25(1), 110-115.
275. Winter, H. R.; Unadkat, J. D. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab. Dispos., 2005, 33(7), 969-976.
276. Parte, P.; Kupfer, D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab. Dispos., 2005, 33(10), 1446-1452.
277. Attar, M.; Dong, D.; Ling, K. H.; Tang-Liu, D. D. Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab. Dispos., 2003, 31(4), 476-481.
278. Ikeda, K.; Yoshisue, K.; Matsushima, E.; Nagayama, S.; Kobayashi, K.; Tyson, C. A.; Chiba, K.; Kawaguchi, Y. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P450 2A6 in human liver microsomes in vitro. Clin. Cancer Res., 2000, 6(11), 4409-4415.
279. Komatsu, T.; Yamazaki, H.; Shimada, N.; Nakajima, M.; Yokoi, T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos., 2000, 28(12), 1457-1463.
280. Yang, T. J.; Shou, M.; Korzekwa, K. R.; Gonzalez, F. J.; Gelboin, H. V.; Yang, S. K. Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem. Pharmacol., 1998, 55(6), 889-896.
281. Vickers, A. E.; Sinclair, J. R.; Zollinger, M.; Heitz, F.; Glanzel, U.; Johanson, L.; Fischer, V. Multiple cytochrome P450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab. Dispos., 1999, 27(9), 1029-1038.
282. Dansette, P. M.; Amar, C.; Smith, C.; Pons, C.; Mansuy, D. Oxidative activation of the thiophene ring by hepatic enzymes. Hydroxylation and formation of electrophilic metabolites during metabolism of tienilic acid and its isomer by rat liver microsomes. Biochem. Pharmacol., 1990, 39(5), 911-918.
283. Belghazi, M.; Jean, P.; Poli, S.; Schmitter, J. M.; Mansuy, D.; Dansette, P. M. Use of isotopes and LC-MS-ESI-TOF for mechanistic studies of tienilic acid metabolic activation. Adv. Exp. Med. Biol., 2001, 500, 139-144.
284. Lopez Garcia, M. P.; Dansette, P. M.; Valadon, P.; Amar, C.; Beaune, P. H.; Guengerich, F. P.; Mansuy, D. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur. J. Biochem., 1993, 213(1), 223-232.
285. Bonierbale, E.; Valadon, P.; Pons, C.; Desfosses, B.; Dansette, P. M.; Mansuy, D. Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. Chem. Res. Toxicol., 1999, 12(3), 286-296.
286. Lasker, J. M.; Wester, M. R.; Aramsombatdee, E.; Raucy, J. L. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch. Biochem. Biophys., 1998, 353(1), 16-28.
287. Venkatakrishnan, K.; von Moltke, L. L.; Greenblatt, D. J. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J. Pharm. Sci., 1998, 87(7), 845-853.
288. Wester, M. R.; Lasker, J. M.; Johnson, E. F.; Raucy, J. L. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab. Dispos., 2000, 28(3), 354-359.
289. Komatsu, K.; Ito, K.; Nakajima, Y.; Kanamitsu, S.; Imaoka, S.; Funae, Y.; Green, C. E.; Tyson, C. A.; Shimada, N.; Sugiyama, Y. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab. Dispos., 2000, 28(4), 475-481.
290. Miners, J. O.; Rees, D. L.; Valente, L.; Veronese, M. E.; Birkett, D. J. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther., 1995, 272(3), 1076-1081.
291. Vermeir, M.; Hemeryck, A.; Cuyckens, F.; Francesch, A.; Bockx, M.; Van Houdt, J.; Steemans, K.; Mannens, G.; Aviles, P.; De Coster, R. In vitro studies on the metabolism of trabectedin (Yondelis) in monkey and man, including human CYP reaction phenotyping. Biochem. Pharmacol., 2009, 77(10), 1642-1654.
292. Tanaka, E.; Kurata, N.; Yasuhara, H. Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J. Clin. Pharm. Ther., 2003, 28(6), 493-496.
293. Damsten, M. C.; de Vlieger, J. S.; Niessen, W. M.; Irth, H.; Vermeulen, N. P.; Commandeur, J. N. Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome P450s. Chem. Res. Toxicol., 2008, 21(11), 2181-2187.
294. Lai, W. G.; Zahid, N.; Uetrecht, J. P. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J. Pharmacol. Exp. Ther., 1999, 291(1), 292-299.
295. Eagling, V. A.; Howe, J. L.; Barry, M. J.; Back, D. J. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3′-amino-3′-deoxythymidine. Biochem. Pharmacol., 1994, 48(2), 267-276.
296. Becquemont, L.; Funck-Brentano, C.; Jaillon, P. Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. Fundam. Clin. Pharmacol., 1999, 13(2), 232-236.
297. Baer, B. R.; DeLisle, R. K.; Allen, A. Benzylic oxidation of gemfi-brozil-1-O-β-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem. Res. Toxicol., 2009, 22(7), 1298-1309.
298. Fischer, V.; Johanson, L.; Heitz, F.; Tullman, R.; Graham, E.; Baldeck, J. P.; Robinson, W. T. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P450 and implications for metabolic drug interactions. Drug Metab. Dispos., 1999, 27(3), 410-416.
299. Prueksaritanont, T.; Zhao, J. J.; Ma, B.; Roadcap, B. A.; Tang, C.; Qiu, Y.; Liu, L.; Lin, J. H.; Pearson, P. G.; Baillie, T. A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther., 2002, 301(3), 1042-1051.
300. Prueksaritanont, T.; Tang, C.; Qiu, Y.; Mu, L.; Subramanian, R.; Lin, J. H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos., 2002, 30(11), 1280-1287.
301. Cai, X.; Wang, R. W.; Edom, R. W.; Evans, D. C.; Shou, M.; Rodrigues, A. D.; Liu, W.; Dean, D. C.; Baillie, T. A. Validation of (-)-N-3-benzyl- phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes. Drug Metab. Dispos., 2004, 32(6), 584-586.
302. Lu, P.; Schrag, M. L.; Slaughter, D. E.; Raab, C. E.; Shou, M.; Rodrigues, A. D. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab. Dispos., 2003, 31(11), 1352-1360.
303. Donato, M. T.; Jimenez, N.; Castell, J. V.; Gomez-Lechon, M. J. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab. Dispos., 2004, 32(7), 699-706.